Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15

Benzinga · 3d ago
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $15.